Comparing the current results to its competitors, Axsome Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 45.54 % year on year. The sales growth was above Axsome Therapeutics Inc 's competitors' average revenue growth of 18.4 %, achieved in the same quarter.
Axsome Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive central nervous system (CNS) market characterized by rapid technological changes. Competitors include pharmaceutical, biotechnology, and specialty pharmaceutical companies, as well as academic institutions, governmental agencies, and public and private research organizations. Many competitors possess extensive drug pipelines, substantial financial resources, and established research and development capabilities. Competition occurs across research and development, manufacturing, clinical trials, regulatory approvals, marketing, personnel recruitment, and acquisition of complementary technologies. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Additionally, small or early-stage companies can be significant competitors, particularly through collaborations with larger firms.
November 26, 2024
Innovative Frontiers: Axsome Therapeutics’ Advancements in Treating Central Nervous System Disorders This article discusses the recent advancements announced by Axsome Therapeutics in targeting central nervous system (CNS) disorders, primarily through the successful completion of primary endpoints in their novel treatments for narcolepsy and the initiation of a new trial for binge eating disorder (BED). It critically evaluates the outcomes of the long-term ENCORE Phase 3 trial for AXS-12 in treating narcolepsy, explores the significance of the SYMPHONY Phase 3 trial, and delves into the promising potential of solriamfetol as treatment for BED. These innovations mark substantial progress in managing compl...
March 25, 2024
Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness (EDS) and a dysregulation of the sleep-wake cycle, often accompanied by sudden muscle weakness or paralysis known as cataplexy. The treatment options available for narcolepsy are limited, urging the need for innovative therapeutic approaches. Recently, Axsome Therapeutics announced encouraging results from the SYMPHONY Phase 3 Trial, showcasing the potential of AXS-12 as a promising candidate for managing narcolepsy. This article aims to analyze the trial s outcomes and present a comprehensive evaluation of AXS-12 s efficacy in reducing cataplexy attacks compared to a placebo.Methods and Design of the SYMPHONY Trial:T...
March 19, 2024
Axsome Therapeutics, a renowned biopharmaceutical company focused on advancing cutting-edge therapies to address central nervous system disorders, is set to revolutionize the treatment landscape for Major Depressive Disorder (MDD). The company has recently announced the commencement of the PARADIGM Phase 3 trial for their investigational drug, solriamfetol, offering new hope to patients suffering from MDD.Axsome s Advanced Therapy Approach:Axsome Therapeutics has garnered a reputation for its dedication in developing and delivering novel therapies specifically designed for the management of central nervous system disorders. The initiation of the PARADIGM trial marks a significant milestone in the journey tow...
Xenon Pharmaceuticals Inc operates in the biopharmaceutical industry, with a focus on discovering and developing innovative therapeutics. Their business model centers around leveraging their proprietary discovery platform to identify and advance potential drug candidates to address unmet medical needs. Through collaborations, licensing agreements, and internal development efforts, Xenon aims to bring new treatments to patients and create value for their stakeholders.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
Harmony Biosciences Holdings Inc's business model revolves around the development and commercialization of innovative therapies for patients with sleep disorders.
Ionis Pharmaceuticals Inc is a biopharmaceutical company that operates on a two-fold business model. Firstly, the company focuses on discovering and developing antisense drugs, utilizing a unique RNA-targeted technology. Secondly, Ionis collaborates with established pharmaceutical partners to license and commercialize their drugs, allowing for maximum reach and potential commercial success.
Sources:
Axsome Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Axsome Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
